Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Hairy Cell Leukemia

Review the hairy cell leukemia treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-10 of 10

Vemurafenib and Obinutuzumab versus Standard Cladribine and Rituximab of the Treatment of Untreated Hairy Cell Leukemia
Status: Active
Location: 7 locations
Venetoclax for the Treatment of Patients with Relapsed Hairy Cell Leukemia
Status: Active
Location: 12 locations
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Active
Location: 5 locations
Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Recurrent or Refractory B Cell Lymphomas
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Study for Patients with Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination with Rituximab and Compare the Combination with Current Standard Treatment
Status: Active
Location: See ClinicalTrials.gov